---
title: "HC Wainwright & Co. maintains Buy rating on ArriVent BioPharma, $27 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301259987.md"
description: "HC Wainwright & Co. maintained a Buy rating on ArriVent BioPharma with a $27 price target, implying 59.9% upside. The firm cites positive FURVENT trial data showing firmonertinib's efficacy and promising preclinical results for next-generation ARR-217 in colorectal cancer, supporting long-term growth outlooks."
datetime: "2026-10-08T10:32:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301259987.md)
  - [en](https://longbridge.com/en/news/301259987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301259987.md)
generator: "portal-rs"
---

# HC Wainwright & Co. maintains Buy rating on ArriVent BioPharma, $27 price target

HC Wainwright & Co. maintained their Buy rating on ArriVent BioPharma's stock with a price target of $27.00.

The price target implies an upside of 59.9% from the Oct 7 close of $16.89.

**Key takeaways from the analyst note**

**Positive Clinical Data from FURVENT Trial**: Despite narrowly missing its primary endpoint, the FURVENT trial demonstrated notable clinical benefits, with firmonertinib achieving an 11.0-month median progression-free survival (mPFS) compared to 9.5 months for the chemotherapy control arm. This suggests potential effectiveness and positions the drug favorably within a competitive landscape.

**Promising Pipeline Developments**: Investor focus is shifting towards ARR-217, a next-generation antibody-drug conjugate showing robust preclinical tumor growth inhibition in colorectal cancer models. With initial clinical data expected in 2027, the potential for innovative treatments enhances the long-term growth outlook for ArriVent BioPharma, supporting a Buy rating.

Explore more price target data and ratings for ArriVent BioPharma on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AVBP.US](https://longbridge.com/en/quote/AVBP.US.md)

## Related News & Research

- [ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low](https://longbridge.com/en/news/301066580.md)
- [ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint](https://longbridge.com/en/news/301032671.md)
- [ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer](https://longbridge.com/en/news/301620875.md)
- [ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)](https://longbridge.com/en/news/301079950.md)
- [‘There’s a Solid Argument,’ Says Investor About Sandisk Stock](https://longbridge.com/en/news/301601315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**